drugset

Drugs / Dendritic Cell Fusion Vaccine

Follow last change Dec 2025 re-read 2 minutes ago

Dendritic Cell Fusion Vaccine

also known as Myeloma vaccine

Developed for: plasma cell myeloma
Investigated by: Blood and Marrow Transplant Clinical Trials Network · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · National Marrow Donor Program

Trials 1 · a red edge is where a trial was stopped

today NCT02728102 · Ph 2

2017201820192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT02728102	Jul 2016 → Jun 2020	plasma cell myeloma	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT01067287 Comparator	Mar 2010 → Sep 2025	plasma cell myeloma	Beth Israel Deaconess Medical Center	Completed	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Dendritic Cell Fusion Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01067287 ↗
Known as	Myeloma vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02728102 ↗
Modality	Vaccine	“The dendritic cell fusion vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells.” NCT01067287 ↗
Route	Subcutaneous	“Vaccine will be administered by subcutaneous injection in the upper thigh.” NCT02728102 ↗